| Literature DB >> 33919242 |
Mario Rothbauer1,2,3, Barbara E M Bachmann1,2,4, Christoph Eilenberger1,2, Sebastian R A Kratz1,2,5, Sarah Spitz1,2, Gregor Höll1,2, Peter Ertl1,2.
Abstract
Organ-on-a-chip technology has the potential to accelerate pharmaceutical drug development, improve the clinical translation of basic research, and provide personalized intervention strategies. In the last decade, big pharma has engaged in many academic research cooperations to develop organ-on-a-chip systems for future drug discoveries. Although most organ-on-a-chip systems present proof-of-concept studies, miniaturized organ systems still need to demonstrate translational relevance and predictive power in clinical and pharmaceutical settings. This review explores whether microfluidic technology succeeded in paving the way for developing physiologically relevant human in vitro models for pharmacology and toxicology in biomedical research within the last decade. Individual organ-on-a-chip systems are discussed, focusing on relevant applications and highlighting their ability to tackle current challenges in pharmacological research.Entities:
Keywords: bioprinting; body-on-a-chip; heart-on-a-chip; kidney-on-a-chip; liver-on-a-chip; lung-on-a-chip; micro-physiological systems; organs-on-a-chip; skin-on-a-chip
Year: 2021 PMID: 33919242 PMCID: PMC8143089 DOI: 10.3390/mi12050470
Source DB: PubMed Journal: Micromachines (Basel) ISSN: 2072-666X Impact factor: 2.891